AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 221 min read$RVTY

Gonzales Anita sold $9K of RVTY

Gonzales Anita (Vice President and CAO) sold 85 shares of REVVITY, INC. (RVTY) at $109.48 on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gonzales Anita
Published Jul 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RVTY
Neutral
high confidence
Mentioned
$RVTY
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

The disclosure provides transparency on an officer’s planned selling activity but does not introduce new company fundamentals or catalysts.

02

Market read

Primarily informational for insider-trading trackers; limited expected impact on trading decisions.

03

What to watch

The sale size is small ($9.3K) and does not include any buy/sell pattern context beyond this single transaction.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-07-22 after-hours, reflecting a 2026-07-20 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Revvity, Inc.

Company-level read

Ticker impact

$RVTYNeutralHigh confidence
Context

Revvity CAO Anita Gonzales sold 85 shares on 2026-07-20 at $109.48/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small, pre-planned open-market sale by an officer, with no accompanying guidance, operational change, or enforcement action disclosed.

Market effects

Sector

No sector read-across; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with private concerns; traders may still monitor for follow-on sales.

Key entities

  • Equity issuer
    RVTY

    Revvity, Inc., the issuer of the Form 4 insider transaction.

  • Insider
    Anita Gonzales

    Vice President and CAO who sold 85 shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVTY insider trading history →

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min